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Background: The drug treatments of choice for obsessive-compulsive disorder (OCD) are serotonin reuptake inhibitors
(SRIs). However, a correlation between the neuropeptide oxytocin in cerebrospinal fluid and the severity of OCD has
previously been shown, and oxytocin and serotonin are interconnected within the brain. Few studies have investigated
whether SRIs have any effect on oxytocin; thus, our aim was to explore the possibility that oxytocinergic mechanisms
contribute to the anti-obsessive effect of SRIs.
Method: In a randomized, double-blind trial, comparing SRIs (clomipramine and paroxetine) with placebo in 36 adults
with OCD (characterized for subtypes), plasma oxytocin was measured with radioimmunoassay after plasma extraction,
at baseline, after 1 week, and after 4 weeks of treatment, and related to baseline severity and clinical response after
12 weeks, as measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).
Results: Baseline oxytocin levels correlated positively with baseline Y-BOCS ratings, but only among the future SRI
responders. Patients with early onset of OCD had higher baseline oxytocin. During treatment, plasma oxytocin did not
differ between SRI and placebo treatment. In SRI responders, plasma oxytocin first decreased and then increased; in
non-responders (to SRI as well as to placebo), the reverse was the case. After 4 weeks, treatment responders had
attained higher oxytocin levels compared to non-responders. The intra-individual range (i.e. the variability) of plasma
oxytocin between measurements was the measure that best differentiated responders from non-responders. This range
was higher in responders than non-responders, and lower in patients with autistic traits.
Conclusions: SRIs have highly variable effects on plasma oxytocin between individuals. The associations between
baseline oxytocin and OCD severity and between oxytocin changes and treatment response support the notions that
oxytocin is involved in OCD pathophysiology, and that the anti-obsessive effects of SRIs are partly exerted through
oxytocinergic mechanisms.
Keywords: Obsessive-compulsive disorder, Oxytocin/plasma, Serotonin, Serotonin uptake inhibitors, Treatment
response, Randomized controlled trial, Autism spectrum disorder, Placebo responseBackground
Obsessive-compulsive disorder (OCD) is a fairly com-
mon psychiatric disorder with variable severity [1]. The
course is often chronic, and OCD is commonly comor-
bid with depression [2]. Furthermore, the clinical picture
of OCD is heterogeneous and various subtypes charac-
terized by concurrent tics, autistic traits, poor insight,* Correspondence: mats.humble@oru.se
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reproduction in any medium, provided the orand obsessive-compulsive personality disorder have been
proposed [3-8]. At an early stage, the initial findings that
clomipramine has a specific anti-obsessive effect di-
rected the focus of neurochemical hypotheses on OCD
towards the monoamine serotonin [9-12]. Subsequent
research on the psychopharmacology of OCD has to a
great extent been determined by the well-documented
effect of serotonin reuptake inhibitors (SRIs, e.g. clomip-
ramine and the selective serotonin reuptake inhibitors
(SSRI)), leaving the serotonergic hypothesis of OCD as
the most influential [13,14]. However, up to 50% ofl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[13,15], and, even if indications of dopamine and glu-
tamate involvement are acknowledged, no consensus
exists whether other effects, downstream of the SRI-
induced changes of serotonin availability, are involved in
the clinical benefit [16,17].
The nonapeptide oxytocin is one of the candidates,
possibly involved in obsessive-compulsive neurochemical
pathways [16,18,19]. Oxytocin is released from hypothal-
amic neurons in the paraventricular (PVN) and supra-
optic (SON) nuclei via axon terminals in the posterior
pituitary as a hormone into the peripheral plasma pool.
In addition, the same magnocellular neurons of these
nuclei exert somatodendritic volume transmission of
oxytocin, contributing to diffuse and long-lasting effects
in adjacent brain areas [20,21] and also to the oxytocin
content of the cerebrospinal fluid (CSF). More recently,
evidence for immediate, targeted, “wired” transmission
of oxytocin has been presented; axonal projections,
mainly from PVN, connect directly with the central nu-
cleus of amygdala, nucleus accumbens, ventral hippo-
campus, and other brain areas where oxytocin receptors
are present [22-24]. Peripherally, there is paracrine/auto-
crine synthesis of oxytocin in the female and male geni-
tal tracts, the pancreas and the heart [25,26], but their
contribution to plasma levels is unknown.
When it comes to cerebral functions, research indi-
cates that oxytocin promotes innate mechanisms for
maternal, affiliative, pro-social, sexual/reproductive and
aggressive behaviors and social recognition [27-29]; a de-
ficiency of some of these functions being relevant for
autism spectrum disorders (ASD) [29,30]. On the other
hand, increased oxytocin induced behaviors and cogni-
tions, related to maternal, affiliative, grooming [19,31]
and sexual functions, may appear similar to several core
symptoms of OCD. Consequently, Leckman et al. hy-
pothesized that some forms of OCD may represent an
over-expression of such oxytocin related innate mecha-
nisms [18]. However, as OCD and ASD often co-occur
[4-6,32-34] the opposite directions of their purported
oxytocinergic derangements may seem paradoxical.
Treatment with intranasal oxytocin was reported to
improve OCD in an early case report [35], but two nega-
tive randomized, placebo-controlled trials refute this
finding [36,37]. Moreover, it is unclear how intranasal
administration of oxytocin affects the oxytocinergic
transmission in relevant parts of the brain [38,39]. CSF
levels of oxytocin have been measured in OCD patients,
also with inconsistent results. In the study by Swedo
et al. [40], CSF-oxytocin of 43 children/adolescents cor-
related positively with depression, but not with OCD
symptom severity. In the next study [41], CSF-oxytocin
was elevated compared to controls in 22 OCD adult sub-
jects without history of tic disorders, and in thesepatients CSF-oxytocin was also positively related to
OCD severity, as measured by the Yale-Brown Obsessive
Compulsive Scale (Y-BOCS). This finding supported the
above mentioned oxytocinergic OCD hypothesis [18],
but a subsequent study [42] found no CSF-oxytocin dif-
ference between OCD and control cases and no relation
to Y-BOCS ratings, however, only 14 patients with OCD
were included. More recently, an animal model was re-
ported [19], supporting that oxytocin gives rise to
grooming compulsions through links between the PVN
and the central nucleus of amygdala.
Several mechanisms connecting serotonin and oxytocin
in the brain have been reported [43-46], and oxytocin has
even been suggested to mediate the therapeutic effects
of SSRIs [47,48]. Serotonin 1A receptors (5-HT1A) are
probably the main mediators of the effect of serotonin
on oxytocin neurons (at least acutely), but also 5-HT2C
and 5-HT4 seem to be of importance [43,49,50]. In
OCD, long-term SSRI treatment has been shown to
down-regulate 5-HT1A receptors [51], likely to decrease
hypothalamic oxytocin out-put [44]. However, it has
been suggested that the clinical benefit in OCD results
from a down-regulation of presynaptic 5-HT1D recep-
tors in the orbitofrontal cortex, leading to increased
transmission over postsynaptic 5-HT2A receptors [14].
Concerning serotonin and peripheral oxytocin, plasma
oxytocin in rats increased within one hour of adminis-
tration of the SSRIs citalopram or zimelidine [47], while
it was unchanged when oxytocin was assessed after
10 days of fluoxetine administration [52], suggesting
that timing is important when assessing the effects of
antidepressants on plasma oxytocin.
To our knowledge, only three previous studies have in-
vestigated oxytocin changes during SRI treatment in
humans. In the first of these [53] 16 children/adolescents
with OCD were studied. Clomipramine treatment, ran-
ging between 8.5 and 34 months, caused an overall in-
crease of CSF oxytocin by 11%. Intriguingly, however,
the individual clinical response was negatively correlated
to CSF oxytocin changes, i.e. those with the least in-
crease of CSF-oxytocin were the most improved. Since
this study only included treatment responders and no
placebo group, conclusions on the pharmacological ef-
fects of SRIs on the oxytocin system should be viewed
with caution. In the next study [54], plasma oxytocin
was measured in 40 patients with major depression be-
fore and after successful treatment, which was SRIs
(venlafaxine or SSRI) in 19 cases. When compared to a
control group, the patients had significantly lower
plasma oxytocin at baseline, however, no difference be-
tween pre-treatment and post-treatment oxytocin levels
was found. All included patients were treatment re-
sponders, and the time span between samples was not
conveyed. Recently, a third study [55] reported on
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treatment in 16 adult patients that were successfully
treated for major depressive disorder. No difference was
found. Consequently, in none of these three studies was
placebo-treated patients used as control, nor were re-
sponders compared to non-responders. Two of them
dealt with depression and only one [55] applied a fixed
time interval for the second oxytocin sample.
In summary, we still do not know whether oxytocin is
critically involved in OCD pathogenesis or not, and if so,
whether the oxytocinergic activity should be increased,
decreased, or changed in other ways in order to improve
the clinical state. Furthermore, the effects of SRI treat-
ment on the human oxytocinergic system are still poorly
characterized, since no study has explored differences
between antidepressants and placebo, or temporal
changes during the early phases of treatment.
Aims
We wanted to explore whether pre-treatment plasma
oxytocin is related to OCD severity and other clinical
features in adult patients with OCD, as compared to pre-
vious studies of CSF oxytocin. Furthermore, we planned
to investigate in a placebo controlled trial whether SRI
treatment in humans are linked to changes of plasma
oxytocin and, if so, the direction and magnitude of these
changes. Finally, we aimed at testing the hypothesis that
oxytocin changes correlate with and possibly predict
anti-obsessive response, by following the temporal pat-




In a multicenter drug trial, carried out 1992–1993, com-
paring paroxetine with clomipramine and placebo for
the treatment of OCD [56], our center included some
biochemical measurements in addition to the blood
samples for safety measures. The blood samples were
taken at baseline (before any drug treatment), after
1 week and after 4 weeks of drug treatment. This sched-
ule was chosen in order to detect early changes of bio-
chemical measures that could possibly predict the
clinical response after 12 week’s treatment. The blood
samples were analyzed in 1995.
Patient population
Details on the inclusion of 36 patients in this biochem-
ical extension of the drug trial have been published else-
where [57]. Briefly, patients could be included if they
fulfilled DSM-III-R criteria for OCD (the DSM-III-R and
DSM–IV criteria for OCD are widely viewed as inter-
changeable [58]) with at least 6 months’ duration and
consented to the blood sampling. Customary exclusioncriteria were applied. At the time of inclusion, no patient
had been taking antidepressant agents of any kind dur-
ing the preceding three months, and two thirds (n = 24)
were SRI treatment naïve. Females in reproductive age
were ascertained not to be pregnant and informed to use
effective contraceptive methods, if applicable. For demo-
graphic data, see Table 1.
Ethics
The study was approved by the Research Ethical Commit-
tee of the Karolinska Institutet, Stockholm, Sweden, and
informed consent was obtained from all participants.
Drug administration
After randomization (2:1:1 ratio), double-blind drug
treatment was given for 12 weeks with increasing, flex-
ible doses of either paroxetine 20–60 mg/day (n = 18),
clomipramine 50–250 mg/day (n = 9) or placebo (n = 9).
Zopiclone 7.5 mg h.s. for insomnia was permitted, if ne-
cessary, but cognitive or behavioral psychotherapy was
not allowed during the study. For clinical results, see
Table 1 and [57].
Assessment instruments
Clinical data including OCD history, severity and subtype
were recorded in a standardized, semi-structured way.
The following rating instruments were used: Y-BOCS
[59], in order to quantify OCD symptom severity and to
evaluate treatment response; National Institute of Mental
Health Global Obsessive Compulsive Scale (NIMH-
GOCS) [60], a complementary method to measure global
severity of OCD; Montgomery Åsberg Depression Rating
Scale (MADRS) [61], a clinician rated instrument for
measuring depressive symptoms, and the Patients’ Global
Evaluation (PGE), a self-rating version of the 7 graded
Clinical Global Impression-Improvement scale [62]. Poor
insight was evaluated clinically, and autistic traits were
assessed with assistance of the High-functioning Autism/
Asperger syndrome Global Scale (HAGS) [33]. It covers
functional impairment, social and emotional reciprocity,
social competence, interests, rigidity, values, self-reflection,
speech and language, body posture, gestures, facial ex-
pression, and eye contact. The rating consists of four dif-
ferent levels: 1 = an exceptionally empathic and socially
competent personality; 2 =more or less normal, “like
most people”; 3 = an emotionally blunt and pathological
personality with autistic traits, clearly noticeable during
the interview; and 4 = an extremely odd personality; the
person gives a peculiar, and clearly autistic, impression
early in the interview. A HAGS score of 3 or more was
considered as sign of autistic traits. Eleven patients were
assessed as having autistic traits. To our knowledge, at
least five of these patients were later formally diagnosed
with ASD.




Paroxetine n = 18 Clomipramine n = 9 Placebo n = 9 Statistical
significance
Sex, males/females, n (% males) 17/19 (47) 8/10 (44) 7/2 (78) 2/7 (22) ns
Age, years 40.7 ± 12.7 38.7 ± 11.8 41.0 ± 13.5 44.6 ± 14.3 ns
OCD, age of onset, years 14.5 ± 6.5 15.2 ± 5.1 13.3 ± 8.7 14.2 ± 7.3 ns
OCD duration, years 26.2 ± 14.8 23.4 ± 13.7 27.6 ± 15.3 30.3 ± 16.8 ns
Y-BOCS, baseline 25.3 ± 5.9 24.6 ± 5.7 24.8 ± 6.8 27.2 ± 5.7 ns
Y-BOCS,% decrease, LOCF 34 ± 27 41 ± 31 38 ± 20 17 ± 21 ns
Y-BOCS,% decrease, completersa 44 ± 26 n = 24 51 ± 24 n = 14 56 ± 10 n = 4 22 ± 25 n = 6 F: 4.1 (2, 21)*
MADRS, baseline 12.2 ± 7.8 10.2 ± 6.4 8.4 ± 3.6 19.9 ± 8.7 F: 8.6 (2, 33)***
MADRS, endpoint, LOCF 8.3 ± 6.8 5.8 ± 5.6 9.3 ± 8.1 12.1 ± 6.2 ns
Premature discontinuation, n (%)b 12 (33) 4 (22) (4, 8, 8, 10 w) 5 (56) (1, 2, 8, 10, 10 w) 3 (33) (10, 10, 10 w) ns
PGE, 1 or 2 at endpoint, n (%) 18 (50) 11 (61) 5 (56) 2 (22) ns
Responders, n (%) 17 (47) 11 (61) 5 (56) 1 (11) χ2: 6.4 (2)*
Numbers are mean values ± standard deviations, unless otherwise specified.
Statistics for comparisons between groups: F = one-way ANOVA statistics for continuous measures; χ2 = Pearson’s chi-squared test for categorical measures.
LOCF = endpoint data, calculated from 12 weeks’ ratings or last observation carried forward; MADRS =Montgomery Åsberg Depression Rating Scale; OCD =
obsessive-compulsive disorder; PGE = Patient’s Global Evaluation; Y-BOCS = Yale-Brown Obsessive Compulsive Scale; Y-BOCS% decrease = endpoint Y-BOCS score
related to Y-BOCS at baseline.
aCompleters continued their randomized treatment for 12 weeks.
bNumbers within second parentheses represent the number of weeks of double-blind treatment for each individual discontinuer.
*p < 0.05; **p < 0.01; ***p < 0.001; ns = non-significant.
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Treatment response was defined as at least 25% decrease
of scores on the Y-BOCS in conjunction with a rating of
1 or 2 (“very much improved” or “much improved”, re-
spectively) on the PGE at endpoint. For premature dis-
continuers, the last observations were carried forward.
PGE, rather than the clinician’s rating of global improve-
ment was chosen in order to also take the patient’s opin-
ion into account. Applying these criteria, 17 of the 36
patients (59% of SRI treated patients) responded to
treatment.
Oxytocin analysis
Blood samples were obtained by cubital venepuncture,
between 8 h00 and 9 h00 a.m., when patients had been
fasting from midnight and before the morning dose of
medication was taken. The sampling was performed by
one of two nurses, known to the patients, on each occa-
sion in the same quiet room, at normal room temperature
and under comfortable circumstances. Samples were
taken at baseline, after 1 week’s double-blind treatment
and after 4 weeks of treatment. The samples were col-
lected in tubes containing heparin (10 IU/mL) and Trasy-
lol (500 IU/mL) and centrifuged. Plasma was separated,
frozen at −70°C, and blindly analyzed in the same assay in
1995. The concentration of oxytocin was measured with a
specific radioimmunoassay (RIA) described by Stock and
Uvnäs-Moberg [63]. Briefly, plasma samples were ex-
tracted on SEP-PAK C18 cartridges prior to assay. Therecovery of this extraction procedure was 95.3 ± 10.1%.
For the assay, antiserum K19 (Milab, Malmö, Sweden)
was used, which has a cross-reactivity at 70% relative
binding (B/BQ) of 0.01% with arginine(A)-vasopressin,
<0.01% with lysine(L)-vasopressin and 0.1% with A-
vasotocin. The limit of detection is 2 fmol/ml and the
intra- and inter-assay coefficients of variation are 11.2 and
13.0% respectively.
Data analysis
Based on previous literature, no prediction of the ex-
pected direction of findings was possible. The patients
treated with paroxetine and clomipramine were initially
analyzed separately, but when they were compared on
relevant parameters no meaningful differences between
these two groups were found. As the clomipramine
cases, when adjoined, did not change the results of the
paroxetine cases, these two treatment groups were
merged to the SRI group, having the same putative
mechanism of action [13,14]. Since most oxytocin mea-
surements were non-normally distributed, all oxytocin
values are reported as medians with 1st and 3rd quartiles
in parentheses, and nonparametric tests (Mann–Whitney
U-test (MW) and Spearman Rank Order Correlation)
were utilized. For other group comparisons one-way
ANOVA or Chi-2 statistics were used. ANOVA of re-
peated measures of the oxytocin changes turned out in-
valid due to the non-normal distributions. This and low
sample size prevented multivariate methods to be used.
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ferences between the repeated measures are reported.
Also, we calculated the intra-individual range (the differ-
ence between the maximal and minimal plasma oxytocin
levels among each patient’s three (n = 32) or two (n = 4)
samples over the 4 weeks), intended to be a measure of
flexibility or responsivity of the oxytocinergic system. The
data on age of onset were categorized into tertiles, which
corresponded to childhood, adolescence and adult onset,
respectively. Statistica 64, version 10, StatSoft Inc. was
used. Probabilities < 0.05 were assumed as significant and,
when relevant, Bonferroni’s adjustment for multiple com-
parisons was judiciously implemented. However, due to
the explorative nature of this study, also the non-adjusted
results are presented.
Results
Baseline oxytocin and clinical features of OCD
Plasma oxytocin at baseline was non-normally distrib-
uted and had a median of 31.3 (22.7, 39.5) pg/ml and a
mean of 33.4 (±13.5). The distribution appeared bi- or
trimodal, with a distinct high mode (50–67 pg/ml) and
two less distinct lower modes (16–25 and 27–41 pg/ml,
respectively); see Table 2 and Figure 1. Oxytocin at base-
line was positively related to baseline Y-BOCS scores inTable 2 Demographics and clinical characteristics according t
All patients
n = 36 Low m
16.6-
Sex, males/females, n (% males) 17/19 (47) 5
Age, years 40.7 ± 12.7 37
Cohabiters/singles, n (% cohab.) 20/16 (44) 9
Any divorce, yes/no, n (% yes) 10/26 (28) 5
Having children, yes/no, n (% yes) 18/18 (50) 5
Number of children 1.0 ± 1.2 0
Full time work, yes/no, n (% yes) 13/22 (37) 4
OCD, age of onset, years 14.5 ± 6.5 1
OCD duration, years 26.2 ± 14.8 21
Familial OCD, yes/no, n (% yes) 14/10 (58) 6
History of tics, yes/no, n (% yes) 8/26 (24) 2
Autistic traits, yes/no, n (% yes) 11/23 (32) 5
History of poor insight, yes/no, n (% yes) 6/27 (18) 1
Y-BOCS score, baseline 25.3 ± 5.9 2
NIMH-GOCS score, baseline 9.4 ± 2.0 8
MADRS score, baseline 12.2 ± 7.8 1
Previous SRI treatment, yes/no, n (% yes) 12/24 (33) 3
Mean values ± standard deviations unless otherwise stated. In Chi-2 and one-way ANO
for cohabitation the overall result was χ2 = 4.7 (2), p = 0.09, and comparison between t
MADRS =Montgomery Åsberg Depression Rating Scale; NIMH-GOCS = National Insti
compulsive disorder; SRI = serotonin reuptake inhibitors; Y-BOCS = Yale-Brown Obsethe total group (Spearman’s rho = 0.35, n = 36, p = 0.037).
The future SRI responders accounted for this correlation
(rho = 0.58, n = 16, p = 0.019), that was not retrieved
among non-responders (rho = 0.17, n = 19, p = 0.48). On
the other hand, baseline oxytocin was unrelated to the
future response to treatment, to depression scores
(MADRS), sex, age, duration of OCD, history of tics,
poor insight, autistic traits and family history of OCD.
The age at OCD onset, however, was negatively corre-
lated to baseline oxytocin (rho = −0.36, n = 36, p =
0.030). Median plasma oxytocin of the 12 cases with
childhood onset (before 11 years) was higher, 35.4 (31.7,
47.3) pg/ml compared to 21.3 (19.0, 35.6) among the 11
patients with adult onset (from 18 years), MW Z = 2.12,
p = 0.034. Baseline plasma oxytocin was also higher
among those completing the 12 weeks’ trial, 34.7 (25.8,
40.0) compared to trial discontinuers, 24.2 (20.5, 30.2),
MWZ = 2.06, p = 0.039.
The distinct higher mode of oxytocin (50 – 67 pg/ml)
contained 6 individuals, that did not differ from the
lower modes, separately or merged (16 – 41 pg/ml) per-
taining to the above mentioned clinical variables; how-
ever 5 of the 6 were cohabiting, a significantly higher
rate compared to the lower modes (χ2 = 4.41, d.f. = 1, p =











/8 (38) 10/7 (59) 2/4 (33)
.6 ± 12.2 43.5 ± 12.6 39.4 ± 14.7
/4 (31) 10/7 (41) 1/5 (83)
/8 (38) 5/12 (29) 0/6 (0)
/8 (38) 10/7 (59) 3/3 (50)
.7 ± 0.9 1.2 ± 1.4 1.0 ± 1.1
/9 (31) 7/9 (44) 2/4 (33)
6.2 ± 4.7 13.7 ± 7.6 13.0 ± 6.8
.4 ± 14.9 29.8 ± 13.6 26.4 ± 17.1
/3 (67) 5/6 (45) 3/1 (75)
/11 (15) 3/12 (20) 3/3 (50)
/8 (38) 5/10 (33) 1/5 (17)
/11 (8) 4/11 (27) 1/5 (17)
3.5 ± 6.2 25.5 ± 5.8 28.8 ± 4.7
.8 ± 2.2 9.6 ± 1.7 10.2 ± 2.1
2.2 ± 8.4 12.2 ± 8.4 12.2 ± 5.9
/10 (23) 6/11 (35) 3/3 (50)
VA tests, all the comparisons of these three groups were non-significant. However,
he highest mode and the merged lower modes resulted in χ2 = 4.4 (1), p = 0.036.



























Figure 1 Correlation between baseline severity of OCD and baseline plasma oxytocin according to SRI response. Severity of OCD is
indicated by total score on the Y-BOCS. Due to non-normal distribution of oxytocin, non-parametric analyses were performed; in the figure,
however, a regression line for the SRI responders derived from a Pearson’s correlation (y = 4,5445 + 1,2468*x; r = 0,42; p = 0,10) is included. Spearman’s
correlation statistics for the various groups: The entire sample: rho = 0.35, n = 36, p = 0.037. SRI responders: rho = 0.58, n = 16, p = 0.019. SRI non-
responders: rho = 0.24, n = 11, p = 0.47. Placebo treated: rho = −0.18, n = 9, p = 0.64. OCD= obsessive-compulsive disorder; SRI = serotonin reuptake
inhibitor; Y-BOCS = Yale-Brown Obsessive Compulsive Scale.
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Out of the initial 36 patients, oxytocin samples were ob-
tained from 35 patients after 1 week and from 33 after
4 weeks. Plasma oxytocin medians in the total group
after 1 and 4 weeks were 31.2 (22.8, 43.8) and 36.7 (27.0,
43.6), respectively. Median oxytocin plasma levels at the
three time points for SRI treated versus placebo treated
patients, respectively, were: baseline 32.1 (22.7, 39.5) vs
31.2 (22.6, 39.5), after 1 week 30.4 (22.5, 40.5) vs 36.1
(25.1, 47.3), after 4 weeks 36.7 (27.3, 43.8) vs 37.0 (26.1,
43.6), and intra-individual range 11.6 (5.1, 16.8) vs 7.4
(5.8, 12.4). None of these measures or the differences be-
tween time point measures differed significantly between
treatment groups. Also, when the clomipramine group
and the paroxetine group were analyzed separately, no
significant differences between them or between them
and the placebo group were detected on the different
oxytocin measures. According to plasma drug levels at
week 4, all SRI patients but one non-responder seemed
to comply with treatment.
Temporal changes of oxytocin related to anti-obsessive
response
While the baseline and week 1 samples did not differ be-
tween responders and non-responders, the 17 treatment
responders (including 1 placebo responder) had higher
oxytocin at week 4, than the 16 non-responders (MW Z=
2.31, p = 0.021, missing data = 3). This difference remained
if only SRI-treated subjects were included in the analysis
(16 responders and 8 non responders) (MW Z= 2.14, p =
0.032, missing data = 3).The individuals’ changes of plasma oxytocin between
the three time points were analyzed and compared be-
tween response groups (Table 3). A significant associ-
ation appeared between final treatment response and the
difference of plasma levels between week 1 and week 4,
showing an increase of oxytocin among treatment re-
sponders and a decrease among non-responders (8.5
(−2.9, 17.5) and −3.1 (−7.5, 2.8), respectively, MW Z =
2.24, p = 0.025). The sole placebo responder had an in-
crease of oxytocin within the highest quartile between
baseline and week 4. The intra-individual plasma oxyto-
cin range significantly differentiated responders from
non-responders in the total group (median 24.2 (15.7,
37.5) vs 8.9 (4.9, 12.7) pg/ml (MW Z= 3.61, p = 0.0003).
Furthermore, this oxytocin range also differed between
those with autistic traits (n = 11) and those without (5.1
(3.5, 9.7) vs 15.6 (7.6, 27.3) MW Z= 2.76, p =0.006, miss-
ing data = 2). With Bonferroni adjustment, the two latter
findings remained significant.
There was a strong negative correlation between both
Y-BOCS and NIMH-GOCS% decrease at endpoint and
plasma oxytocin change between baseline and first week
of SRI treatment; i.e. those with the largest initial in-
crease of plasma oxytocin had the poorest outcome. Re-
versely, a strong positive correlation was found between
oxytocin change between week 1 and 4 and overall im-
provement in OCD symptoms. None of these measures
correlated with improvement of depressive symptoms.
The oxytocin range correlated strongly with improve-
ment in OCD and to a lesser extent also with amelior-
ation of depression (Table 4 and Figure 2).
Table 3 Plasma oxytocin in OCD patients: temporal changes according to response category and treatment








MW: Z, pa MW: Z, pb MW: Z, pc
Oxytocin baseline, n = 36 31.3 (22.7, 39.5) 36.0 (25.8, 39.9) 24.5 (19.7, 33.7) 31.2 29.6 (22.3, 39.6) 1.44, 0.15 1.55, 0.12 −0.45, 0.65
Oxytocin week 1, n = 35 31.2 (22.8, 43.8) 30.9 (21.1, 42.6) 30.4 (23.5, 37.4) - 36.1 (25.1, 47.3) −0.78, 0.44 −0.47, 0.64 −0.37, 0.71
Oxytocin week 4, n = 33 36.7 (27.0, 43.6) 40.1 (30.0, 53.8) 29.4 (23.7, 35.6) 43.6 35.3 (24.1, 42.3) 2.31, 0.021 2.14, 0.032 −0.68, 0.49
Change from baseline to week 4
(OT-4 – OT-0) n = 33
0.8 (−3.0, 5.6) 1.4 (−6.5, 11.5) 2.4 (−1.3, 4.9) 12.4 −1.9 (−2.7, 2.6) 0.52, 0.60 0.0, 1.0 0.58, 0.56
First week change (OT-1 – OT-0) n = 35 2.8 (−3.8, 5.2) −5.7 (−13.2, 6.8) 3.7 (2.2, 5.0) - 2.4 (0.0, 4.8) −1.36, 0.17 −1.09, 0.28 0.87, 0.39
Change from week 1 to week 4
(OT-4 – OT-1) n = 32
1.8 (−6.8, 11.4) 8.5 (−2.9, 17.5) −0.8 (−5.9, 2.8) - −4.7 (−7.5, 3.3) 2.24, 0.025 1.99, 0.047 0.26, 0.79
OT range, n = 36 10.1 (5.5, 16.4) 15.7 (11.8, 25.0) 5.0 (3.7, 9.7) 12.4 6.8 (4.5, 17.5) 3.61, 0.0003 3.38, 0.0007 0.54, 0.59
Numbers are medians (1st and 3rd quartiles). Bolded numbers and texts indicate significant findings. Plasma oxytocin is reported as pg/ml. For response criteria, see Methods.
a: comparison between all responders and all non-responders.
b: comparison between SRI responders and SRI non-responders.
c: comparison between non-responders to SRI and non-responders to placebo.
Only one patient responded to placebo and, hence, is only included in the first (a) statistical analysis. In comparisons between all SRI treated and all placebo treated patients, no significant differences appeared for
any of the oxytocin measures.
MW=Mann Whitney statistics; OCD = obsessive-compulsive disorder; OT = plasma oxytocin; OT-0 = baseline sample; OT-1 = week 1 sample; OT-4 = week 4 sample; OT range = intra-individual range between the maximal and


































OT baseline, n = 27 0.23 −0.05 0.52** 0.25 −0.33
OT week 1, n = 27 −0.34 −0.18 0.25 −0.22 0.04
OT week 4, n = 24 0.31 0.15 0.43* 0.43* −0.49*
OT change from baseline to week 4, n = 24 −0.14 −0.14 −0.13 −0.20 0.12
OT first week change, n = 27 −0.49** −0.13 −0.15 −0.40* 0.26
OT change from week 1 to week 4, n = 24 0.58** 0.26 −0.02 0.46* −0.38
OT range, n = 27 0.59** 0.49** 0.38 0.67*** −0.66***
Only patients treated with SRI are included (n = 27). Nonparametric correlations (Spearman’s rho) are reported. Bold-italic numbers indicate correlations that
remained significant after Bonferroni adjustment, when applied for the first two columns.
MADRS =Montgomery Åsberg Depression Rating Scale; NIMH-GOCS = National Institute of Mental Health Global Obsessive Compulsive Scale; PGE = Patient’s Global
Evaluation; OCD = obsessive-compulsive disorder; OT = plasma oxytocin; OT range = intra-individual range between the highest and the lowest of each patient’s 3
(n = 24) or 2 (n = 3) OT samples; SRI = serotonin reuptake inhibitor; Y-BOCS = Yale-Brown Obsessive Compulsive Scale.
*p < 0.05; **p < 0.01; ***p < 0.001.
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There were no significant correlations between the pre-
viously reported [57] measures of serotonin in whole
blood from the same patients and the presently reported
oxytocin measures. Specifically, neither the baseline
serotonin level nor the decrease of serotonin between
baseline and week 1 (that correlated with clinical im-
provement) showed any connection with the oxytocin
measures (all Spearman rho values below 0.10), indicat-
ing that these measures are independent.
Discussion
To our knowledge, this is the first placebo controlled
study investigating the effect of SRIs on oxytocin mea-



















Figure 2 Plasma oxytocin changes in responders and non-responders
during the first four treatment weeks, among SRI responders (SRI+, n = 16),
placebo non-responders (PLC-, n = 8), respectively. Mann Whitney statistics we
were found: at week 4 between all responders and all non-responders (as sho
the change from week 1 to week 4 between SRI responders and non-respond
at week 1 was missing for the only placebo responder; oxytocin at week 4 wa
PLC = placebo. *p < 0.05.null finding could be due to the limited sample size or
other methodological factors. However, the result may
be interpreted as reflecting a marked individual variabil-
ity regarding the reactivity of the oxytocinergic system,
due to e.g. genetic factors. In support of this, the individ-
uals with autistic traits had significantly lower intra-
individual oxytocin range compared to the others.
On the other hand, we have shown highly significant
correlations between dynamic changes of plasma oxyto-
cin during the first four weeks of SRI treatment and sub-
sequent clinical improvement of OCD. This correlation
was most pronounced for the range of oxytocin changes:
those patients whose oxytocin varied most were also
those most improved on all OCD severity measures.






to SRI or placebo treatment. Mean plasma oxytocin levels (pg/ml)
SRI non-responders (SRI-, n = 11), placebo responder (PLC+, n = 1) and
re used because of non-normal data distribution. Significant differences
wn in graph); at week 4 between SRI responders and SRI non-responders;
ers (all p < 0.05); for statistical details see Table 3. Missing data: oxytocin
s missing in 3 other patients. SRI = serotonin reuptake inhibitor;
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responders (Figure 2). For non-responders, this oxytocin
pattern was almost identical for SRI-treated and placebo-
treated cases. The one placebo responder seemed to
follow the pattern of the SRI responders, with a large ele-
vation of oxytocin levels during treatment, although, un-
fortunately, the crucial one-week sample was missing in
this very case.
Since SRI treatment per se did not induce significant
changes of plasma oxytocin as compared to placebo, our
interpretation is that the findings indicate an association
between plasma oxytocin changes and some sequence of
events within the brain specifically involved in the anti-
obsessive response to SRIs. Specificity for anti-obsessive
effects is supported by the considerably lower, mostly in-
significant correlations between oxytocin measures and
the changes of MADRS scores. The one correlation that
emerged may well be the result of depression attenu-
ation, secondary to the OCD improvement. Since plasma
oxytocin constitutes only an indirect representation of
cerebral events, the nature and direction of these events
cannot be resolved from our study. Hypothetically, our
data may have resulted from temporal processes (e.g.
changes of receptor sensitivities), where the oxytocin
system in general changed its activity in opposite direc-
tions (due to e.g. genetic polymorphisms) among re-
sponders compared to non-responders, the net result
being an increased activity. However, in the only relevant
previous study [53], CSF-oxytocin increased overall
among clomipramine responders, but the best anti-
obsessive response was correlated with the least increase
or even decrease of CSF-oxytocin. CSF and plasma both
constitute imperfect “windows” through which to look at
processes in relevant parts of the brain, each summing
up different compartment activities. Then, both study
results could be explained if an “OCD-crucial” part of
the oxytocin system decreased its activity, while other
parts non-specifically increased their. In the CSF study,
only those with the most significant improvement may
have decreased their “OCD-crucial” production suffi-
ciently to prevail over the non-specific increase. In our
study, supposedly, the “OCD-crucial” decrease started
early on, noticeable after one week, while the non-
specific increase lagged after. In any case, our findings
may indicate that the oxytocin neurons in responders
are more responsive to serotonergic influence than those
in non-responders, as indicated by their wider range of
oxytocin levels.
Another finding was the replication of a positive rela-
tionship between oxytocin levels and Y-BOCS scores in
untreated OCD patients, as found by Leckman et al.
[41]. In their study, however, this relation was only
present in non-tic -related OCD. As seen in Table 2 and
Additional file 1: Figure S1, we could not identify anydifference of this relation between subtypes. On the other
hand, we found a negative association between baseline
oxytocin and age at OCD onset, possibly due to a wider
range in our study. Since childhood onset OCD may have
different etiological factors, e.g. autoimmune mechanisms,
these may hypothetically be associated with higher plasma
oxytocin. Unfortunately, no data on possible autoimmune
OCD was available concerning our patients. A difference
between our studies is that Leckman and coworkers mea-
sured oxytocin in CSF while the present study was based
on plasma levels. In our study, however, the more compel-
ling correlation in future SRI responders and lack of cor-
relation in SRI non-responders may be interpreted as
support for a “neuroendocrine subtype” of OCD, where el-
evated oxytocin may be involved, and which is associated
with SRI response.
Central versus peripheral oxytocin compartments
In the present study it was not possible to identify intra-
cerebral events; thus the nature of the implied central
nervous counterparts giving rise to and mediating our
plasma findings is an unresolved issue. Almost all
plasma oxytocin is released from the magnocellular neu-
rons in the SON and PVN via the posterior pituitary.
The functional links between the neurohypophyseal re-
lease and the intra-cerebral circuits operating with oxy-
tocin are as yet poorly understood; but even if they
could be regulated separately [20,23,26], they are most
likely to interact. In a study were both CSF and plasma
oxytocin levels were analyzed in the same individuals
[64], central and peripheral oxytocin measures did not
correlate with each other, while both correlated with
some measures of suicidality. In various experiments, el-
evated oxytocin has been linked to relaxed, affiliative sit-
uations, implying anxiolytic and antidepressant effects
[47,65], but in other experiments oxytocin is increased
in relation to stress [26,66]. These disparate findings in-
dicate that different segments of the central oxytocin
system may act in different directions. The difficulty of
predicting effects within the oxytocinergic system is fur-
ther underscored by recent studies were intranasal oxy-
tocin induced lowered mood in women with postnatal
depression [67], and increased agonistic behaviors with
dysregulated HPA axis in piglets [68], respectively, in
both cases contrary to expectation.
Possible influence of the clinical setting and affiliative
aspects
In 1992, when the patients in this study were enrolled,
OCD was regarded as a rare disorder and many psychia-
trists in Sweden were not aware that they had treated
any OCD patients in their practice. Therefore, most of
the patients were recruited through advertisement in the
local paper, and only a handful was clinically referred.
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were mostly in their early forties, they had a mean dur-
ation of OCD of 26 years and one third was defined as
depressed. Just about half the sample was able to work
full time and the majority lived as singles. Most of these
patients had not conveyed their symptoms prior to this
study, possibly due to shame. Now, they were assigned a
well-informed and devoted psychiatrist that fully under-
stood their symptoms and provided hope for improve-
ment. Such circumstances are often put forward in
discussions of problematic placebo response in random-
ized controlled trials. However, in our study, the rate of
placebo response was very low, in accordance with the
clomipramine studies of the early days [69]. In spite of
this, the social bonding and affiliative aspects of the clin-
ical setting could hypothetically have enhanced oxytocin
release and thus influenced the results, resulting in the
increase of plasma oxytocin that we saw the first week in
both placebo treated patients and SRI non-responders.
However, in the SRI responders, the decrease of plasma
oxytocin at week 1 may correspond to a response-related
serotonin-oxytocin interaction that surmounted this af-
filiative effect. In this perspective, it may also be of interest
that the patients that completed 12 weeks of double-blind
treatment had higher baseline oxytocin than those that
did not. Nonetheless, the substantial increase of plasma
oxytocin in our only placebo responder suggests that
oxytocin may be relevant for future studies on placebo re-
sponse. Incidentally, the relevance of our oxytocin mea-
surements for affiliative aspects was corroborated by the
higher number of married or cohabiting individuals in the
group with highest baseline oxytocin.
Implications for anti-obsessive SRI mechanisms
According to El Mansari and Blier [14], the neuro-
physiological change, responsible for improvement in
SRI treatment of OCD, is that orbitofrontal pre-synaptic
5-HT1D receptors are down-regulated by long term
(8 weeks) treatment with SRIs. This will lead to an in-
creased transmission over 5-HT2 receptors, eventually
leading to decreased activity in the “OCD loop”, consist-
ing of orbitofrontal cortex, the head of the caudate nu-
cleus, a direct and an indirect pathway through the basal
ganglia, the thalamus, and back to orbitofrontal cortex.
It remains a possibility that our changes of oxytocin
plasma levels only represent peripheral reflections of
such serotonergic events without any functional import-
ance. However, the baseline correlation with OCD sever-
ity in our and a previous study [41] supports the view
that the oxytocinergic system is not merely a bystander.
An alternative hypothesis would be that down-
regulation of post-synaptic 5-HT1A receptors, which is
known to take place in the hypothalamus during SRI
treatment [51], will result in decreased oxytocinergictransmission in relevant parts of the forebrain. The cred-
ibility of this hypothesis, though, depends on conceivable
links between the oxytocinergic system and the above
mentioned, well documented OCD neural circuit. Even
if no evidence was found for frontal cortex oxytocin re-
ceptors in an autoradiography study of humans [70],
more recently and with more advanced technology oxy-
tocinergic fibers of medium density were identified in
the medial orbital and the frontal association cortices of
rats [23]. Moreover, in a recent study, intranasal oxyto-
cin challenge in humans caused an increased activity of
the caudate nucleus (an essential part of the OCD neural
circuit), and a significant correlation between plasma
oxytocin and caudate activity was reported [71]. Also,
nucleus accumbens has been implicated in OCD [72]
and receives oxytocinergic innervation from the PVN. It
has even been shown that oxytocin and serotonin inter-
act closely in the nucleus accumbens, related to social
reward [73]. Accordingly, it is not inconceivable that
overactive oxytocinergic neurons of hypothalamic origin
contribute to OCD severity by increasing striatal and
orbitofrontal engagement. In such case, a SRI-induced
down-regulation of hypothalamic 5HT1A receptors [51]
may modulate this oxytocinergic over-activity, thereby
eventually contributing to an anti-obsessive response.
Since the magnocellular neurons in the PVN transmit
oxytocin both by axons projecting to amygdala and nu-
cleus accumbens and by hormonal release into the per-
ipheral circulation [22,23], changed regulation of their
central activity may well be reflected in plasma oxytocin
levels. However, there is a lack of detailed knowledge on
the regulation of these separate activities, especially con-
cerning the effects of SRIs. Admittedly, it is reasonable
that the entire oxytocinergic system change synchro-
nized under the influence of SRI treatment, but the pos-
sibility remains that different parts of the system react
differently to serotonergic changes. In such case, the
already discussed, seemingly contradictory findings of
OCD-oxytocin relationships in the present and a previ-
ous study [53] may find an explanation. However, until
future studies have shed more light on the regional seroto-
nergic regulation of oxytocin transmission, and the effects
of psychopharmacological manipulations, this remains
conjecture.
On the other hand, increased oxytocin activity has
been linked to anxiolytic effects, exerted e.g. in the
amygdala [23] or the median raphe nucleus [45], effects
that may also be involved in the reduction of OCD
symptoms. Then, the oxytocin decrease in responders
after 1 week’s treatment could hypothetically be linked
to an increase in anxiety. Interestingly, when starting
SRI treatment in panic disorder, an initial paradoxical in-
crease of anxiety is commonly observed [74,75], how-
ever, this is less commonly reported in OCD treatment.
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present study, we do not know whether the initial de-
creases of oxytocin correspond to increases of anxiety. If
this were the case, however, oxytocin deficit may con-
tribute to an explanation of this intriguing phenomenon.
Further relevance for connections between serotonin
and oxytocin in the human brain has been demonstrated
by mechanistic studies of 3,4-methylenedioxymetham-
phetamine (MDMA or “Ecstasy”). It has been shown in
humans that one of the acute effects of MDMA intake is
elevation of plasma oxytocin together with pro-social ef-
fects [e.g. 76]. Since MDMA purportedly exerts its ef-
fects through the serotonin transporter and SRI
pretreatment blocked the oxytocin elevation, the authors
suggest a primary role for serotonin in the effects of
MDMA on oxytocin release. According to Hunt et al.
[77], MDMA-induced increase of oxytocin depends on
5-HT1A transmission and takes place in the SON and
PVN. Interestingly, two cases where MDMA use was re-
lated to de novo onset of OCD have been reported [78],
seemingly consistent with our hypothesis.
One further link between OCD psychopharmacology
and oxytocin is provided by the effects of antipsychotic
drugs. In OCD, resistant to SRI treatment, the best docu-
mented treatment option is to add an antipsychotic; both
haloperidol and risperidone have strong short-term data,
while those of olanzapine and quetiapine are mixed [17].
Conversely, in patients with schizophrenia, obsessive-
compulsive symptoms may emerge related to anti-
psychotic use, the risk seemingly higher with clozapine
and olanzapine than with haloperidol and risperidone
[79,80]. The effects of these antipsychotics on the oxytocin
system have been investigated [81,82], showing most
markedly increased release of oxytocin and activation of
oxytocinergic neurons by clozapine, closely followed by
olanzapine, while the effects of risperidone and haloperidol
were much less pronounced or absent. Accordingly, if oxy-
tocin contributes to obsession and compulsion severity,
this may explain the differential effects of antipsychotics as
SRI augmentation in OCD treatment as well as de novo
OCD provocation among patients with schizophrenia.
Thus, we suggest that the present study supports the
idea that oxytocin is involved in OCD, but based on our
data we cannot conclude on the preferred direction of
oxytocin changes during OCD treatment. However, glean-
ings from other research shift the balance in the direction
of an increased activity of some part of the central oxyto-
cin system in OCD, as previously proposed [18,19,39], and
that this activity is moderated by SRI treatment.
Limitations
This study includes a small sample of patients and it was
carried out in the early nineties. On the other hand, con-
sidering how widely spread SSRI medication is today, itwould be a challenge to obtain a group of mainly drug
naïve, chronically ill patients such as those included in
the present study. The small sample size is to some ex-
tent compensated by the low placebo response, as is vali-
dated by the significantly higher response rate with SRI
compared to placebo treatment. Also, since the two ac-
tive treatments did not differ on any relevant measures,
they were merged in order to increase statistical power.
Because the placebo group remained problematically
small, the comparisons with placebo should be seen as
tentative; however, the response categories within the
SRI group have a more reasonable size.
Oxytocin in plasma was measured at three time points;
however, in four patients it was only measured twice due
to patient related factors. All samples were obtained dur-
ing the first 4 weeks of SRI treatment; it would have
been of interest to measure oxytocin also after 12 weeks
in order to follow further changes. However, our meas-
urement schedule was based on the presumption that
the biochemical changes appearing during the first phase
of treatment are decisive for treatment result; further-
more the risk of drop-outs increases with the length of
the study. Oxytocin was only measured in plasma; it
would have been preferable to also include CSF levels,
but most patients with OCD are likely to refuse spinal
tap due to extensive worries regarding its consequences.
Oxytocin is released in a pulsatile manner and may also
vary in relation to the menstrual cycle and use of oral
contraceptives. These factors were not accounted for in
the present study, but it seems unlikely that the correla-
tions to response would have appeared as a spurious re-
sult of this omission. On the other hand, the RIA
method we used for oxytocin analysis, including plasma
extraction, belongs to the most reliable types of oxytocin
analysis [83]. The importance of plasma extraction for
the validity of these analyses has recently been further
emphasized [84]. Furthermore, a link between our oxy-
tocin measurements and mental functions is to some ex-
tent validated by the association between oxytocin levels
and cohabitation status, in line with previous research;
see e.g. [85,86].
Recent findings suggest specific interactions between
genetic polymorphisms of the serotonin transporter and
oxytocin receptor genes [46], which would have been in-
teresting to explore in our patient group. However, at
the time of our study such genotyping was not available.
The lack of a relationship between depressive symp-
toms and oxytocin measures may be due to our patients’
low but variable levels of depressive symptoms, thus
representing a type II error. Finally, we did not use spe-
cific rating scales for tics, and autistic traits were only
measured with a global scale, HAGS. Again, at the time of
the study, other instruments for assessing ASD in adults
with normal intellectual ability were not developed.
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The effect of SRIs on the oxytocinergic system is com-
plex, and more research is needed to disentangle the net
effects in different parts of this system.
The baseline correlation of oxytocin levels and OCD se-
verity, as well as the highly significant associations be-
tween changes of oxytocin levels and anti-obsessive (but
not anti-depressive) treatment response, support the no-
tion that oxytocin is involved in the pathophysiology of
OCD and, furthermore, that oxytocin is involved in the
anti-obsessive effect of SRI. Indeed, our findings suggest
the possible existence of an oxytocin related neuroendo-
crine subtype of OCD, perhaps associated with childhood
onset. But neither whether OCD is related to an increased
or decreased oxytocinergic activity, nor what part of the
oxytocinergic system that is mainly involved, is resolved
by this study. When related to previous work, however,
our most parsimonious interpretation posits an overactive
segment of the oxytocinergic system that is down-
regulated by long-term SRI treatment. Recently available
oxytocin receptor agonists and antagonists as well as
genotyping for the oxytocin receptor would be of interest
for further explorations of the connections between sero-
tonergic and oxytocinergic mechanisms in OCD and re-
lated disorders. Also, oxytocin sampling schedules that
cover both the pulsatile release and the temporal changes
of oxytocin regulation, suggested by the present study,
may further elucidate this issue. Taken together, our find-
ings suggest that OCD should be included in translational
research on oxytocin involvement in psychiatric disorders.
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Additional file 1: Correlation between baseline plasma oxytocin
and baseline severity of OCD according to OCD subtypes. Severity of
OCD is indicated by total score on the Y-BOCS. Subtypes of OCD are
indicated by symbols (see legend). Spearman’s rho = 0.35, n = 36,
p = 0.037. OCD = obsessive-compulsive disorder; Y-BOCS = Yale-Brown
Obsessive Compulsive Scale; ASD = autism spectrum disorder.
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